Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease (Ment-COPD)
Effect of L-menthol on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease: a Randomized
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Zainab Ahmadi, MD, PhD
- Phone Number: 046171000
- Email: zainab.ahmadi@med.lu.se
Study Locations
-
-
-
Lund, Sweden
- Lund University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The subject has given written consent to participate in the study
- Diagnosis of COPD confirmed by spirometry and a FEV1 < 80% of predicted post bronchodilator at baseline
- age 18 years or older
- able to cycle
- able to understand and talk Swedish to participate in the study procedures, as judged by the Investigator.
Exclusion Criteria:
- Resting peripheral oxygen saturation (SpO2) < 92%
- hospitalization or clinical instability during the last four weeks
- treatment with supplementary oxygen at rest or during exercise
- contraindication to exercise testing in accordance with clinical practice guidelines
- expected survival shorter than six months as judged by the Investigator
- medical conditions including congestive heart failure, acute coronary artery disease, neuromuscular diseases, severe psychiatric illness, and olfaction disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Menthol
In the trial, 30 minutes prior to performing submaximal CPET, participants will be administered, L-menthol patch which will be attached to the inside of a facemask that is connected to the breathing circuit.
|
(Sigma-Aldrich, St. Louis, US)
|
|
Placebo Comparator: Placebo
For placebo, the patch will contain a similarly patch with strawberry scent.
|
Strawberry scent (Sigma-Aldrich, St. Louis, US)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breathlessness intensity
Time Frame: Through study completion, up to 1 year
|
The difference between treatment conditions in dyspnea intensity (Borg CR10 scale) at iso-time.
|
Through study completion, up to 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dyspnea unpleasantness
Time Frame: Through study completion, up to 1 year
|
The difference between treatment conditions in dyspnea unpleasantness (Borg CR10 scale) at iso-time.
|
Through study completion, up to 1 year
|
|
Total time
Time Frame: Through study completion, up to 1 year
|
Time to the limit of tolerance (s) (tLIM)
|
Through study completion, up to 1 year
|
|
Exercise capacity
Time Frame: Through study completion, up to 1 year
|
V'O2 (aerobic exercise capacity, absolute and in %pred)
|
Through study completion, up to 1 year
|
|
Work load
Time Frame: Through study completion, up to 1 year
|
Workload (W and %pred)
|
Through study completion, up to 1 year
|
|
Minute ventilation
Time Frame: Through study completion, up to 1 year
|
Minute ventilation
|
Through study completion, up to 1 year
|
|
Tidal volume (VT)
Time Frame: Through study completion, up to 1 year
|
Tidal volume (VT)
|
Through study completion, up to 1 year
|
|
Ventilatory reserve
Time Frame: Through study completion, up to 1 year
|
Ventilatory reserve, defined as maximal voluntary ventilation (MVV) - VE
|
Through study completion, up to 1 year
|
|
Cardiac reserve
Time Frame: Through study completion, up to 1 year
|
Cardiac reserve, evaluated using the predicted peak heart rate
|
Through study completion, up to 1 year
|
|
Inspiratory capacity
Time Frame: Through study completion, up to 1 year
|
Inspiratory capacity (IC) during exercise
|
Through study completion, up to 1 year
|
|
Breathing frequency
Time Frame: Through study completion, up to 1 year
|
Breathing frequency during exercise
|
Through study completion, up to 1 year
|
|
Peak dyspnea intensity
Time Frame: Through study completion, up to 1 year
|
Dyspnea intensity at peak exercise (Borg CR10)
|
Through study completion, up to 1 year
|
|
Leg discomfort
Time Frame: Through study completion, up to 1 year
|
Leg discomfort (Borg CR10)
|
Through study completion, up to 1 year
|
|
Anaerobic threshold
Time Frame: Through study completion, up to 1 year
|
Timing (and V'O2) of the anaerobic threshold (AT)
|
Through study completion, up to 1 year
|
|
Ventilatory efficacy
Time Frame: Through study completion, up to 1 year
|
Efficacy of ventilation (VE/V'CO2-slope)
|
Through study completion, up to 1 year
|
|
Respiratory exchange ratio
Time Frame: Through study completion, up to 1 year
|
Respiratory exchange ratio (RER), defined as V'CO2/V'O2
|
Through study completion, up to 1 year
|
|
Saturation
Time Frame: Through study completion, up to 1 year
|
O2-saturation
|
Through study completion, up to 1 year
|
|
Stop reason
Time Frame: Through study completion, up to 1 year
|
Causes of stopping the test
|
Through study completion, up to 1 year
|
|
Adverse events
Time Frame: Through study completion, up to 1 year
|
Any adverse events during the test
|
Through study completion, up to 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Zainab Ahmadi, MD, PhD, Region Skane
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pathological Conditions, Signs and Symptoms
- Pulmonary Disease, Chronic Obstructive
- Organic Chemicals
- Lipids
- Hydrocarbons
- Cyclohexanes
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Alcohols
- Cyclohexanols
- Hexanols
- Fatty Alcohols
- Cyclohexane Monoterpenes
- Monoterpenes
- Menthol
Other Study ID Numbers
Other Study ID Numbers
- Ment-COPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.